复方甘草酸苷治疗病毒性肝炎高胆红素血症疗效观察

目的观察复方甘草酸苷治疗病毒性肝炎高胆红素血症的疗效。方法对66例总胆红素〉171μmol／L的病毒性肝炎随机分为2组,治疗组（33例）用复方甘草酸苷注射液（40-120）ml,静滴,1次／天;对照组（33例）用岩黄莲注射液12ml,静滴,1次／天。两组同时应用维生素、能量合剂等,疗程均为4周。比较两组治疗前后的临床症状、体征和肝功能变化等。结果治疗组临床症状、体征改善,治疗前后TBil、ALT、AIJP和γ-GT下降均较对照组明显（P〈0．05）,治疗组总有效率100％,明显高于对照组72．7％（P〈0．01）,差异有统计学意义,未观察到复方甘草酸苷相关的任何不良反应发生。结论复方甘草酸苷治疗病毒性肝炎高胆红素血症有效且安全。     

异甘草酸镁联合丹红注射液治疗病毒性肝炎伴高胆红素血症疗效观察

目的观察异甘草酸镁联合丹红注射液治疗病毒性肝炎伴高胆红素血症患者的疗效。方法将60例病毒性肝炎伴高胆红素血症患者随机分为治疗组30例和对照组30例,对照组给予异甘草酸镁治疗,治疗组在对照组治疗基础上加用丹红注射液,治疗4周。结果在治疗前,两组患者肝功能指标无显著性差异。在治疗4周末,治疗组和对照组患者血清TBIL分别为38.2±50.2μmoL/L和72.0±70.3μmoL/L,ALT分别为70.2±66.8U/L和116.6±100.5U/L,GGT分别为70.2±51.0U/L和122.0±102.8U/L（P〈0.05）。结论异甘草酸镁联合丹红注射液治疗病毒性肝炎伴高胆红素血症患者有较好的疗效。     

熊去氧胆酸联合复方丹参注射液治疗高胆红素血症32例

近年来，国内外针对高胆红素血症治疗采用了多种治疗方法，疗效均不显著，近年来我们应用熊去氧胆酸联合复方丹参注射液治疗高胆红素血症，旨在探讨其在退黄及抗肝纤维化方面治疗效果，为今后肝病治疗开辟一条新方法。现报告如下。     

新生儿高胆红素血症蓝光治疗的观察与护理

目的探讨新生儿高胆红素血症蓝光治疗的护理要点,观察治疗效果。方法对我院68例高胆红素血症患儿进行蓝光治疗并精心护理。结果 68例患儿均治愈,无核黄疸发生。结论新生儿高胆红素血症采用蓝光治疗能有效地降低血清未结合胆红素,减少胆红素脑病发生。在光疗过程中仔细观察患儿病情,采取正确有效的护理措施,预防并发症的发生,促进患儿早日康复。     

新生儿高间接胆红素血症治疗的探讨

目的探讨新生儿高间接胆红素血症(高胆)的治疗方法与疗效.方法对本院2002年1月～2005年1月观察的63例高胆新生儿分药物与光疗两组治疗.结果 3d后间接胆红素下降平均值:药物组为44μmol/L;光疗组为67μmol/L.结论光疗组疗效比药物组为佳(P＜0.05),可列为治疗高胆的首选.     

腺苷蛋氨酸联合复方丹参注射液治疗病毒性肝炎伴高胆红素血症效果观察

我科应用腺苷蛋氨酸联合复方丹参注射液治疗病毒性肝炎伴高胆红素血症患者30例，观察该方案降低血清总胆红素的疗效，现报告如下。     

大黄复方治疗高胆红素血症75例

目的：观察大黄复方对高胆红素血症的治疗效果。方法：在护肝降酶及对症处理的基础上，治疗组用大黄复方治疗，对照组用门冬氨酸甲镁和思美泰，对比两组胆红素消退及疗程的差异和症状体征的改善情况。结果：治疗线在上述各方面都不同程度优于对照组。结论：大黄复方退黄效果肯定。     

新生儿高胆红素血症利用换血疗法治疗的临床护理

目的探析新生儿高胆红素血症利用换血疗法治疗的临床护理方法及效果。方法将我院于2018年2月-2019年3月收治的50例新生儿高胆红素血症患儿作为主要对象,运用数字随机表法分组,各25例。分别给予对照组和观察组患儿常规护理、综合护理,对比两组的干预效果。结果护理后,观察组患儿的直接胆红素水平、间接胆红素水平及总胆红素水平均显著低于对照组,有显著差异(P<0.05);观察组的黄疸恢复时间、蓝光治疗时间相对较短,换血治疗次数更少,有显著差异(P<0.05);观察组的患儿家属满意度评分显著低于对照组,有显著差异(P<0.05)。结论对采用换血疗法治疗的高胆红素血症新生儿实施综合护理干预可辅助提高治疗效果,减少换血治疗次数,且患儿家属的满意度更高,值得推广应用。     

去黄贴剂治疗新生儿高胆红素血症的观察与护理

将120例高胆红素血症患儿随机分为治疗组与对照组,对照组给常规治疗,治疗组常规治疗加去黄贴剂经皮穴位透入。结果显示,治疗组在降低高胆患儿血中胆红素,增加NBNA评分及对逆转脑干听觉诱发电位方面与观察组均有显著差异(P<0.01),同时可缩短住院时间降低治疗费用。认为去黄贴剂治疗高胆红素患儿具有安全、经济、疗效好的特点。     

复方甘草酸苷联合门冬氨酸-鸟氨酸治疗慢性乙型肝炎高胆红素血症48例临床观察

目的 观察复方甘草酸苷联合门冬氨酸-鸟氨酸治疗慢性乙型肝炎高胆红素血症的临床疗效.方法 治疗组:复方甘草酸苷注射液60～80 ml加入10%葡萄糖注射液250 ml静脉点滴(静滴),门冬氨酸-鸟氨酸5～10 g加入10%葡萄糖注射液250 ml,均1/d,4周为1个疗程.对照组:甘草酸二铵注射液150 mg,门冬氨酸钾镁30 ml加入10%葡萄糖注射液250 ml静滴;1/d,4周为1个疗程.均用2个疗程.结果 本组资料结果显示,治疗组的总有效率为89.58%,明显优于对照组(P＜0.05).结论 门冬氨酸-鸟氨酸与复方甘草酸苷联用在改善临床症状和肝功能等方面具有良好的作用.     

复方甘草酸苷片治疗脂肪肝疗效初探

目的观察复方甘草酸苷片对脂肪性肝病的治疗效果及安全性。方法将门诊非病毒性脂肪肝的患者54例随机分为2组,观察组予复方甘草酸苷片治疗,对照组予硫普罗宁片治疗。在相同运动疗法和要求饮食控制的基础上,观察2组患者的肝功能情况及药物的不良反应。结果观察组肝功能复常率、复常时间及疗效稳定性均优于对照组(P<0.05),而药物不良反应则以观察组为少(P<0.05)。结论复方甘草酸苷片治疗非病毒性脂肪性肝炎患者的疗效相对较好,且安全。     

复方甘草酸苷对暴发性肝衰竭患者的保护作用

目的:探讨复方甘草酸苷(StrongerNeo-MinophagenC,SNMC)对暴发性肝衰竭(FLF)患者的保护作用.方法:全部病例均为2003-03/2005-03期间住院的患有急性、亚急性重型肝炎的86例实验分为治疗组和对照组.治疗组每天注射(iv)SNMC120mL,同时采用常规保肝支持对症治疗.对照组则仅用保肝支持对症治疗.对比观察两组的转氨酶(ALT)、胆固醇(CHOL)、总胆红素(TBIL)、凝血酶原活动度(PTA)、肿瘤坏死因子-α(TNF-α)、一氧化氮(NO)、白介素-6(IL-6)的变化情况及病情转归.结果:ALT、TBIL两组比较差异不显著(P>0.05);CHOL、PTA在治疗组的恢复程度(3wk后)明显优于对照组,两组差异显著(P<0.01).两组治疗后,治疗组NO、IL-6水平与对照组相比有显著差异(24.5±18.1μmol/Lvs48.1±24.1μmol/L,P<0.01;76.9±71.2ng/Lvs357.1±79.1ng/L,P<0.01).治疗组有17例治疗无效,病死率为37.8%(17/45),对照组有29例治疗无效,病死率为70.7%(29/41),两组相比差异显著(P<0.01).结论:SNMC对暴发性肝衰竭有明显的保护作用,并抑制各种因素所介导的炎症反应,从而防止或缓解肝坏死及减少并发症,降低病死率.     

复方甘草酸苷对小鼠暴发性肝功能衰竭保护作用及机制研究

目的　探讨复方甘草酸苷(SNMC)对小鼠暴发性肝功能衰竭(FLF)的保护作用及可能机制。方法　用D- 氨基半乳糖和脂多糖腹腔注射构建肝功能衰竭的小鼠模型,同时用SNMC对治疗组小鼠进行保护,观察各组小鼠存活率、肝功能、各种炎症因子及肝脏病理变化;电镜下观察线粒体结构的改变;应用末端转移酶标记技术(TUNEL)检测肝细胞原位凋亡的情况;应用免疫组化法分别检测肝组织中细胞色素C和天冬氨酸半胱氨酸蛋白酶3(caspase 3)的表达。结果　D 氨基半乳糖和脂多糖可以构建FLF模型,SNMC不同剂量组及不同给药时间组在降低酶学指标及血浆肿瘤坏死因子(TNF)- α、NO、内皮素(ET) -1、白细胞介素(IL) 6 水平,改善肝组织的损伤程度方面与模型组比较(多组间方差分析)差异均有统计学意义(P<0.01)。不同剂量和不同给药时间之间差异无统计学意义(P>0.05)。模型组和保护组之间的存活率差异有统计学意义(P<0.01)。同时给药小剂量组随着SNMC治疗时间的延长,凋亡指数逐渐降低,由6- h的32.3%降至7 d的5%(P<0.05);细胞色素C和caspase 3随治疗时间延长表达逐渐减少;电镜可见典型的肝细胞凋亡随治疗时间的延长明显改善。结论　SNMC对小鼠FLF有明显的保护作用,其机制可能是抑制各种因素所介导的炎症反应及通过稳定线粒体膜抑制细胞色素     

Therapeutic effects of Stronger Neo-Minophagen C (SNMC) in patients with chronic liver disease

To evaluate the therapeutic efficacy of Stronger Neo-Minophagen C (SNMC) in patients with chronic liver diseases, a multicenter prospective study was performed in Beijing, China. A total of 109 patients were treated with SNMC intravenous injection and SNMC tablets (Minophagen Pharmaceutical Co., Tokyo, Japan). They responded to the treatment with marked effective rate of 66% and overall effective rate of 75%. SNMC was shown to lower serum ALT and AST levels shortly after the administration, especially for the patients with higher serum levels. Serum bilirubin was reduced simultaneously, and metabolism of protein was improved. SNMC was proved to be safe with minimal side effects.     

复方甘草酸苷与甘草酸二铵治疗慢性乙型肝炎疗效观察

目的观察复方甘草酸苷(美能)与甘草酸二铵治疗慢性乙型肝炎(CHB)患者的疗效,并比较其差异。方法将91例CHB患者分为复方甘草酸苷组和甘草酸二铵组。观察和记录患者症状、体征的变化及药物不良反应,定期检测肝功能、HBV血清免疫学标志物、HBVDNA定量等项目,随访12个月。结果复方甘草酸苷组与甘草酸二铵组总有效率分别为84.09%和80.85%,2组间无显著性差异(P>0.05);2组在AST复常方面有显著性差异(P<0.01);复方甘草酸苷组显效率为72.23%,甘草酸二铵组显效率为57.45%,2组亦有显著性差异(P<0.05)。结论复方甘草酸苷与甘草酸二铵治疗CHB患者均有明显疗效,前者在AST复常方面效果更佳。     

Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis

BACKGROUND: A daily injection of glycyrrhizin (Stronger Neo-Minophagen C (SNMC) containing 40 mg glycyrrhizin in a 20 mL ampoule) lowers alanine aminotransferase (ALT) levels in patients with chronic viral hepatitis. METHODS: The therapeutic effects of intermittent administration of SNMC three times a week for 12 weeks were evaluated and compared between two doses (40 and 100 mL) in a randomized clinical trial. RESULTS: Overall, the therapeutic response was better in the 53 patients allocated 100 mL than the 59 who were allocated to have 40 mL SNMC (P = 0.0243). At the completion of SNMC treatment, ALT levels decreased more extensively in the patients on 100 mL than those on 40 mL SNMC (-29 vs-50% in comparison with the baseline value, P = 0.0002). Minor side-effects occurred in both the patients on 100 mL (20%) and those on 40 mL (12%), but they did not require any therapies. CONCLUSIONS: Intermittent SNMC would be efficient in suppressing ALT levels in patients with chronic viral hepatitis in a dose-dependent manner. Taken along with infrequent and very mild side-effects, long-term intermittent SNMC would benefit patients with chronic hepatitis by maintaining their quality of life with easier compliance.     

Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein.

BACKGROUND/AIM: Stronger Neo-Minophagen C (SNMC), a glycyrrhizin-containing preparation, has been used as a treatment for chronic hepatitis for more than 30 years in Japan, and shown to be effective in preventing the development of hepatocellular carcinoma in chronic hepatitis C patients, but its underlying mechanisms remain elusive. The aim of this study was to investigate if SNMC had an anti-oxidative effect, as oxidative stress has been proposed to be one of the mechanisms of liver injury in hepatitis C virus (HCV)-associated chronic liver diseases. METHODS: The protective effect of SNMC against carbon tetrachloride (CCl4)-induced liver injury was examined using transgenic mice expressing the HCV polyprotein. RESULTS: A small dose of CCl4 (10 microl/kg of body weight) significantly increased the serum alanine aminotransferase (ALT) level and hepatic malondialdehyde content, decreased hepatic reduced glutathione (GSH) content and induced ultrastructural alterations of hepatic mitochondria in transgenic mice, but not in nontransgenic mice. A single SNMC treatment equivalent to a clinical dose significantly restored the serum ALT level and hepatic malondialdehyde and GSH contents, attenuated the ultrastructural alterations of hepatic mitochondria, and increased mRNA expression of gamma-glutamylcysteine synthetase (gamma-GCS). CONCLUSIONS: Transgenic mice expressing the HCV polyprotein are abnormally vulnerable to oxidative stress. SNMC protects hepatocytes against CCl4-induced oxidative stress and mitochondrial injury in the presence of HCV proteins by restoring depleted cellular GSH.     

脑干听觉诱发电位诊断新生儿高胆红素血症的临床应用价值

目的 探讨应用脑干听觉诱发电位(BAEP)诊断新生儿高胆红素血症的临床价值.方法 选择2017-08～2019-08阳春市妇幼保健院收治的98例高胆红素血症新生儿作为观察组,另选择同期98名健康新生儿作为对照组.两组均施行BAEP检测,并比较检测结果.结果 观察组有71例(72.45％)发生BAEP异常,对照组有6例(...